Department of Biochemistry, Microbiology and Immunology, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada.
Biochem Soc Trans. 2024 Feb 28;52(1):395-405. doi: 10.1042/BST20230725.
DDX41 is a DEAD-box helicase and is conserved across species. Mutations in DDX41 have been associated with myeloid neoplasms, including myelodysplastic syndrome and acute myeloid leukemia. Though its pathogenesis is not completely known, DDX41 has been shown to have many cellular roles, including in pre-mRNA splicing, innate immune sensing, ribosome biogenesis, translational regulation, and R-loop metabolism. In this review, we will summarize the latest understandings regarding the various roles of DDX41, as well as highlight challenges associated with drug development to target DDX41. Overall, understanding the molecular and cellular mechanisms of DDX41 could help develop novel therapeutic options for DDX41 mutation-related hematologic malignancies.
DDX41 是一种 DEAD-box 解旋酶,在物种间保守。DDX41 突变与髓系肿瘤有关,包括骨髓增生异常综合征和急性髓系白血病。尽管其发病机制尚不完全清楚,但 DDX41 已被证明具有许多细胞功能,包括在 pre-mRNA 剪接、先天免疫感应、核糖体生物发生、翻译调控和 R-loop 代谢中。在这篇综述中,我们将总结 DDX41 的各种作用的最新认识,并强调针对 DDX41 开发药物的挑战。总的来说,了解 DDX41 的分子和细胞机制可能有助于为 DDX41 突变相关的血液恶性肿瘤开发新的治疗选择。